Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amarin (NASDAQ: AMRN) and Axovant Sciences (NYSE: AXON).
Amarin (NASDAQ: AMRN)
In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Amarin (NASDAQ: AMRN), with a price target of $10. The company’s shares closed on Friday at $3.15.
Chen noted:
“On AMRN’s 1Q18 earnings call 5/2/18, CEO John Thero discussed two large omega-3 trials currently being conducted, VITAL and ASCEND. In short, these two studies are different than AMRN’s outcome study for Vascepa, REDUCE- IT. Therefore, the data readouts for VITAL and ASCEND (good or bad) do not change our positive investment thesis on AMRN’s stock.”
According to TipRanks.com, Chen is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.4% and a 41.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Spero Therapeutics Inc.
Currently, the analyst consensus on Amarin is Strong Buy and the average price target is $9, representing a 185.7% upside.
In a report issued on May 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $10 price target.
See today’s analyst top recommended stocks >>
Axovant Sciences (NYSE: AXON)
Chardan Capital analyst Gbola Amusa maintained a Hold rating on Axovant Sciences (NYSE: AXON) today. The company’s shares closed on Friday at $1.20, close to its 52-week low of $1.02.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 21.7% and a 50.2% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Arbutus Biopharma Corporation.
Axovant Sciences has an analyst consensus of Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
